EU Drug Regulatory Network Faces Up To An Uncertain And Complex Future
Tasks To Be Shared By EMA And National Regulators
Regulators have produced yet another strategy outlining the challenges and next steps for the European drug regulatory network as the network prepares for a future characterized by rapid developments in science and technology, medicines access issues, supply chain weaknesses and emerging health threats.
You may also be interested in...
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.
Participants at a workshop on the EU’s proposed Pharmaceutical Strategy discussed affordability and drug shortages and called for more urgency on the draft HTA regulation.